

**Address: Eightyeight @Kasablanka Office Tower, Lantai 10, Unit E
Jl. Casablanca Kav. 88, Jakarta Selatan 12870, INDONESIA**

Jakarta, April 9th 2025

**Dr. Tedros Adhanom Ghebreyesus
Director-General
World Health Organization**

Subject: Support for the World Federation of Hemophilia's Applications for the WHO Model Lists of Essential Medicines 2025 Update (C.1 Changes to listings of cryoprecipitate, pathogen-reduced cryoprecipitate, and plasma-derived clotting factor concentrates; A.23 Recombinant coagulations factors – haemophilia; A.12 Emicizumab – haemophilia A)

Dear Dr. Tedros Adhanom Ghebreyesus,

I am writing as a representative of the Indonesian Hemophilia Society, the national member organization of the World Federation of Hemophilia (WFH), to express our support for the three applications submitted by the WFH regarding the 2025 update to the WHO Model List of Essential Medicines. The three applications are:


- C.1 Changes to listings of cryoprecipitate, pathogen-reduced cryoprecipitate, and plasma-derived clotting factor concentrates
- A.23 Recombinant coagulations factors – haemophilia
- A.12 Emicizumab – haemophilia A

Advancements in medical technology have significantly improved treatment for people with hemophilia. Prophylactic care, which involves the administration of clotting factor concentrates (CFCs) and factor VIII mimetic bispecific antibodies, is now the global standard of care for hemophilia patients. However, we are concerned by the inclusion of both pathogen-reduced and non-pathogen-reduced cryoprecipitate on the core medicines list of the 2023 Model List, while virally safe plasma-derived CFCs remain categorized as complementary medicines. Cryoprecipitate carries significant risks of transmitting blood-borne infections, such as HIV, hepatitis B, and hepatitis C. Additionally, it cannot be used for prophylactic treatment, making it unsuitable for preventing bleeding-related complications.

The current Model List of Essential Medicines does not reflect the global standard of care or best clinical practices for hemophilia management. Therefore, we urge the WHO to consider the WFH's recommendations as part of the upcoming 2025 revision.

We sincerely hope that the 2025 updates will bring EMLs up to date with current international clinical practice guidelines, ensuring safer and more effective treatments for people with hemophilia and von Willebrand disease.

Sincerely,



**INDONESIAN
HEMOPHILIA
SOCIETY**
Himpunan
Masyarakat Hemofilia
Indonesia

Associate Prof. Novie Amelia Chozie, MD, PhD
President of Indonesia Hemophilia Society